Brukinsa savings card from the maker

How to pay the least

Ask for the cash price

Brukinsa

We didn’t find one.

Ask your pharmacy for Brukinsa’s cash price, and one or two other pharmacies too.

Compare every option

Brand nameBrukinsa

Authorized genericzanubrutinib

Regular genericzanubrutinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Brukinsa?

The original

–

Brand nameThe maker’s card

myBeOne Support Co-Pay Support

Savings card from BeOne Medicines

Brukinsa’s maker has a savings program. Its page doesn’t list a dollar amount.

Or call 1-833-234-4363.

From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.

Authorized genericNot sold

There isn’t one. An authorized generic is Brukinsa itself, from the same company, sold without the brand name, and usually for less. For now Brukinsa is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:

Mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Waldenström's macroglobulinemia (WM).
Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Source: the FDA label for Brukinsa (BeOne Medicines USA, Inc.), September 4, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/brukinsa/